← Clovis Oncology, Inc. (CLVS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Clovis Oncology, Inc. (CLVS)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-01-15 (est.)
Phase 2
Pipeline
12
programs
Upcoming events
3
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2027-01-15 (est.)Phase 2 · Copanlisibimp 7/10
- 2027-01-15 (est.)Phase 2 · rucaparibimp 7/10
- 2027-09-15 (est.)Phase 2 · Trastuzumab and Pertuzumab (combination treatment)imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CO-1.01 | Phase 2 | Metastatic Pancreatic Adenocarcinoma |
| Copanlisib | Phase 2 | Metastatic Castration-resistant Prostate Cancer |
| rucaparib | Phase 3 | Metastatic Breast Cancer |
| Dostarlimab and Niraparib | Phase 2 | Mesothelioma, Malignant |
| Dacomitinib | Phase 2 | Cancer |
| Lorlatinib | Phase 2 | Cancer |
| Selpercatinib | Phase 2 | Cancer |
| Erdafitinib | Phase 2 | Cancer |
| Vemurafenib and Cobimetinib (combination treatment) | Phase 2 | Cancer |
| Regorafinib | Phase 2 | Cancer |
| Trastuzumab and Pertuzumab (combination treatment) | Phase 2 | Cancer |
| Dabrafenib and trametinib | Phase 2 | Cancer |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CLVS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.